Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Coherus Biosciences, retaining the price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of Coherus Biosciences’ innovative oncology pipeline. The recent Nobel Prize in Physiology or Medicine, awarded for discoveries in peripheral immune tolerance and the role of regulatory T cells (Tregs), underscores the relevance of Coherus’ CHS-114, an anti-CCR8 antibody designed to deplete intratumoral Tregs and enhance immune response against tumors. This scientific recognition has brought attention to the therapeutic potential of targeting CCR8, a mechanism that is gaining interest from major pharmaceutical companies.
Furthermore, Coherus is actively advancing CHS-114 in multiple clinical programs, with significant data readouts expected in 2026, which could serve as catalysts for the company’s stock. The company’s transition from biosimilars to a focus on oncology, coupled with the rising investor interest and recent stock performance, supports McCarthy’s optimistic outlook. The upcoming Society for Immunotherapy of Cancer (SITC) events, where Coherus will showcase CHS-114, are expected to further enhance the visibility and credibility of their oncology efforts, reinforcing the Buy recommendation.